NCT03235245
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03235245 |
| Title | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) |
| Acronym | EBIN |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | European Organisation for Research and Treatment of Cancer - EORTC |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU |
CKB BOOST